Aethlon Medical (NASDAQ:AEMD) Shares Cross Below 200 Day Moving Average – Here’s Why

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.02 and traded as low as $0.71. Aethlon Medical shares last traded at $0.73, with a volume of 493,003 shares changing hands.

Analyst Ratings Changes

A number of brokerages recently weighed in on AEMD. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a research note on Thursday, August 14th. Wall Street Zen raised Aethlon Medical to a “sell” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.00.

Aethlon Medical Stock Performance

The company has a 50-day simple moving average of $1.12 and a 200 day simple moving average of $2.02. The company has a market capitalization of $1.90 million, a P/E ratio of -0.06 and a beta of 1.83.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, August 13th. The medical equipment provider reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.17). As a group, sell-side analysts forecast that Aethlon Medical, Inc. will post -0.73 earnings per share for the current year.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Armistice Capital LLC acquired a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,427,946 shares of the medical equipment provider’s stock, valued at approximately $511,000. Armistice Capital LLC owned approximately 8.89% of Aethlon Medical at the end of the most recent quarter. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.